エンザルタミドとカルシウム拮抗薬の薬物相互作用が血圧変動に及ぼす影響

• Material Type: 記事
• Title: エンザルタミドとカルシウム拮抗薬の薬物相互作用が血圧変動に及ぼす影響
• Author Heading: 守田 和憲; 北岡 朋子; 佐々 扶美; 鬼木 健太郎; 猿渡 淳二; 田上 治美
• Publication Date: 2023-02-10
• Publication Date (W3CDTF): 2023-02-10
• Periodical title: 医療薬学
• No. or year of volume/issue: 49 2
• Volume: 49
• Issue: 2
• Pages: 59-65
• Publication date of volume/issue (W3CDTF): 2023-02-10
• ISSN (Periodical Title): 1346342X
• ISSN-L (Periodical Title): 1346342X
• Publication (Periodical Title): Japanese Society of Pharmaceutical Health Care and Sciences
• Text Language Code: ja
• Subject Heading: drug interaction; prostate cancer; enzalutamide; hypertension; calcium channel blocker; cytochrome P450
• Target Audience: 一般
• DOI: 10.5649/jjphcs.49.59
• Related Material (URI): https://www.jstage.jst.go.jp/article/jjphcs/49/2/49_59/_pdf; https://search.jamas.or.jp/link/ui/2023125957
• References: Effect of Comorbidity on Prostate Cancer–Specific Mortality: A Prospective Observational Study; https://cir.nii.ac.jp/crid/1360017981627205120; Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses; https://cir.nii.ac.jp/crid/1360017982286629120; Preventive drugs in the last year of life of older adults with cancer: Is there room for deprescribing?; https://cir.nii.ac.jp/crid/1360017985268677120; Drug–drug interaction potential in men treated with enzalutamide: Mind the gap; https://cir.nii.ac.jp/crid/1360299456605245312; Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis; https://cir.nii.ac.jp/crid/1360299461080270080; Co-morbidities in a Retrospective Cohort of Prostate Cancer Patients; https://cir.nii.ac.jp/crid/1360580933694548224; Enzalutamide in Japanese patients with chemotherapy‐naïve, metastatic castration‐resistant prostate cancer: A post‐hoc analysis of the placebo‐controlled PREVAIL trial; https://cir.nii.ac.jp/crid/1360846643096760192; Impact of enzalutamide and its main metabolite <i>N</i>‐desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters; https://cir.nii.ac.jp/crid/1360855569801777792; Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer; https://cir.nii.ac.jp/crid/1361137043710025344; Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin; https://cir.nii.ac.jp/crid/1361418520570922368; Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy; https://cir.nii.ac.jp/crid/1361981468726289408; ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer; https://cir.nii.ac.jp/crid/1362262945038791808; Evaluation of a Pharmacist-Led Medication Assessment Used to Identify Prevalence of and Associations With Polypharmacy and Potentially Inappropriate Medication Use Among Ambulatory Senior Adults With Cancer; https://cir.nii.ac.jp/crid/1363107368641602816; Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer; https://cir.nii.ac.jp/crid/1363107369007906816; Pharmacokinetic Drug Interaction Studies with Enzalutamide; https://cir.nii.ac.jp/crid/1363951796102461952; General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information; https://cir.nii.ac.jp/crid/1363951796246792064; Enzalutamide in Metastatic Prostate Cancer before Chemotherapy; https://cir.nii.ac.jp/crid/1364233271212775552
• Data Provider (Database): 国立情報学研究所 : CiNii Research
• Original Data Provider (Database): Japan Link Center; https://japanlinkcenter.org/top; Crossref; https://www.crossref.org

• Summary, etc.: <p>Enzalutamide, a potent androgen-receptor inhibitor, is known to induce drug-metabolizing enzymes including cytochrome P450 (CYP) 3A4, 2C9, and 2C19...